复方甘草酸苷注射液对血压及电解质影响的回顾性研究

目的探讨复方甘草酸苷注射液引起血压升高及低钾血症的危险因素,为临床安全用药提供参考。方法回顾性分析300例接受复方甘草酸苷注射液治疗的患者的临床资料,对治疗中并发血压升高及低钾血症的相关危险因素进行二元Logistic回归分析。结果 300例接受复方甘草酸苷注射液治疗的患者血压升高的发生率为18.67%,男性患者更容易并发血压升高(P=0.020),发生血压升高组的患者年龄高于未发生组(62.46±14.18)岁vs.(44.67±20.84)岁,P<0.001],复方甘草酸苷注射液的日剂量较高(72.50±20.38) ml vs.(58.67±26.97) ml,P<0.001],合并高血压的比例较高(30.36%,P<0.001)。二元Logistic回归分析表明,复方甘草酸苷注射液引起血压升高的危险因素包括性别(OR=2.098,95%CI:1.062~4.415,P=0.033)、年龄(OR=2.656,95%CI:1.390~5.079,P=0.003)、日剂量(OR=2.018,95%CI:1.023~3.980,P=0.043)及合并高血压(OR=4.633,95%CI:2.062~10.410,P<0.001)。低钾血症的发生率为12.33%,发生低钾血症组的患者年龄高于未发生组(56.22±13.69)岁vs.(46.86±21.53)岁,P=0.001],复方甘草酸苷的日剂量较高(70.27±19.79) ml vs.(59.96±27.49) ml,P=0.007],使用疗程较长(10.03±7.34) d vs.(7.32±6.74) d,P=0.040],合并高血压的比例较高(21.62%,P=0.035)。二元Logistic回归分析表明,复方甘草酸苷注射液引起低钾血症的危险因素包括年龄(OR=2.131,95%CI:1.058~4.290,P=0.034)及合并高血压(OR=2.515,95%CI:1.042~6.070,P=0.040)。结论临床使用复方甘草酸苷注射液的过程中应监测患者的血压及电解质水平,尤其是男性、年龄>60岁、日剂量>60 ml及合并高血压的患者,应注意血压升高及低钾血症的发生。

A retrospective study on the effect of compound glycyrrhetate injection on blood pressure and electrolyte

Objective To investigate the risk factors for the elevated blood pressure and hypokalemia caused by compound glycyrrhetate injection,and to provide reference for clinical safe medication.Methods The medical records of 300 patients who received compound glycyrrhetate injection therapy were collected and analyzed retrospectively.The risk factors associated with the elevated blood pressure and hypokalemia induced by compound glycyrrhetate injection were identified via Binary Logistic regression analysis.Results The incidence of elevated blood pressure induced by compound glycyrrhetate injection was 18.67%.Male patients(P=0.020)and patients with hypertension(30.36%,P<0.001)were more likely to have elevated blood pressure.Patients with elevated blood pressure were older(62.46±14.18)years vs.(44.67±20.84)years,P<0.001],and had higher daily dosage of compound glycyrrhetate injection(72.50±20.38)ml vs.(58.67±26.97)ml,P<0.001].Binary Logistic regression analysis showed that the risk factors associated with elevated blood pressure induced by compound glycyrrhetate injection were gender(OR=2.098,95%CI:1.062~4.415,P=0.033),age(OR=2.656,95%CI:1.390~5.079,P=0.003),the daily dose of compound glycyrrhetate injection(OR=2.018,95%CI:1.023~3.980,P=0.043)and combination with hypertension(OR=4.633,95%CI:2.062~10.410,P<0.001).The incidence of hypokalemia was 12.33%.Patients with hypokalemia were older(56.22±13.69)years vs.(46.86±21.53)years,P=0.001],had higher daily dosage of compound glycyrrhetate injection(70.27±19.79)ml vs.(59.96±27.49)ml,P=0.007],and had longer course of using compound glycyrrhetate injection(10.03±7.34)d vs.(7.32±6.74)d,P=0.040].Patients with hypertension were more likely to have hypokalemia(21.62%,P=0.035).Binary Logistic regression analysis showed that the risk factors associated with hypokalemia were age(OR=2.131,95%CI:1.058~4.290,P=0.034)and combination with hypertension(OR=2.515,95%CI:1.042~6.070,P=0.040).Conclusion The blood pressure and electrolyte levels should be monitored when compound glycyrrhetate injection is used for clinical therapy.The patients should be closely monitored for elevated blood pressure and hypokalemia when the patient is male,whose age is over 60 years,whose daily dosage is more than 60 ml,and who is with hypertension.